Last reviewed · How we verify
NCT04757727
Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
trial testing Decriptive study of EDB in Dystrophic Epidermolysis Bullosa in 27 participants. Completed in 30 December 2021.
30 September 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 1 January 2021 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Decriptive study of EDB
Conditions studied
- Dystrophic Epidermolysis Bullosa — all drugs for Dystrophic Epidermolysis Bullosa →
Sponsor
Centre Hospitalier Universitaire de Nice
Who can join
18 and older, female only, with Dystrophic Epidermolysis Bullosa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dystrophic epidermolysis bullosa is a rare genetic pathology resulting in fragility of the skin and mucous membranes, causing bubbles and wounds following trauma. Scarring is pathological with a tendency to retraction. The gynecological and in particular the vulvovaginal mucous membranes can be affected but no description of any series is available in the literature. Likewise, some of these patients have a sexual and obstetrical life, despite sometimes-severe damage, but again no specific data is available. The investitigator thus wish to carry out a non-interventional multicenter prospective descriptive study. Better knowledge of gynecological semiology in patients with EBD will allow better adaptation of gynecological follow-up, screening for STDs and gynecological cancers, as well as possible specific complications. This study would eventually allow the draw up of recommendations for our gynecologist / obstetrician colleagues.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Gynaeco-obstetrical follow-up of patients with dystrophic epidermolysis bullosa, a prospective study.
Fournier M, Bourrat E, Rapp J, Vexiau D, et al · · 2025 · PMID 40119383 · DOI 10.1186/s13023-024-03434-0
Verify or expand the search:
- PubMed search for NCT04757727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dystrophic Epidermolysis Bullosa
Currently open trials in the same condition.
- NCT06594393 — A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study · Phase 2 · recruiting
- NCT07230223 — Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa · Phase 1, PHASE2 · recruiting
- NCT05157958 — Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa · Phase 2 · recruiting
- NCT04917887 — Long-Term Follow-up Protocol · recruiting
Other Centre Hospitalier Universitaire de Nice trials
Trials by the same sponsor.
- NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
- NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
- NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04757727 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04757727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing